Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 13/20 | 0.38 |
| ▸ | EHMT1 | Q9H9B1 | 12/20 | 0.38 |
| ▸ | IGF1R | P08069 | 2/20 | 0.37 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25166156 | 1.00 | ABCB1 (0.38) | ABCB1ABCC1ABCG2APOBEC3AAPOBEC3G | |
| SCHEMBL25166581 | 0.90 | HAVCR2 (0.43) | APOBEC3AAPOBEC3GL3MBTL1EHMT2EHMT1 | |
| SCHEMBL30329812 | 0.90 | HAVCR2 (0.43) | APOBEC3AAPOBEC3GL3MBTL1EHMT2EHMT1 | |
| SCHEMBL30329752 | 0.82 | ABCB1 (0.40) | ABCB1ABCC1ABCG2L3MBTL1ALDH1A1 | |
| SCHEMBL25166672 | 0.78 | APOBEC3A (0.36) | APOBEC3AAPOBEC3GL3MBTL1EHMT2EHMT1 | |
| SCHEMBL31108019 | 0.75 | EHMT2 (0.37) | ABCB1ABCC1ABCG2EHMT2EHMT1 | |
| SCHEMBL30329966 | 0.75 | EHMT2 (0.37) | ABCB1ABCC1ABCG2EHMT2EHMT1 | |
| SCHEMBL25166431 | 0.75 | HAVCR2 (0.41) | APOBEC3AAPOBEC3GL3MBTL1EHMT2EHMT1 | |
| SCHEMBL30330177 | 0.75 | HAVCR2 (0.41) | APOBEC3AAPOBEC3GL3MBTL1EHMT2EHMT1 | |
| SCHEMBL25166700 | 0.74 | ALDH1A1 (0.36) | ABCB1ABCC1ABCG2EHMT2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368139-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| CN-118647610-A | Novel modulators of EHMT1 and EHMT2 and therapeutic uses thereof | 探戈医药股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-4416143-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | Tango Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| WO-2023064586-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368139-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | EHMT1, EHMT2, SHMT1 | ABCB1 496/4885ABCC1 324/4885ABCG2 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.